Do elevated levels of serum-soluble Fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?

Journal of Autoimmunity

Volumn 11, Issue 5, 1998, Pages 457-463

  Bijl, Marc ^a   Van Lopik, Th ^b   Limburg, P C ^a   Spronk, P E ^a   Jaegers, S M H J ^c   Aarden, L A ^b   Smeenk, R J T ^b   Kallenberg, G G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Beatrixoord Cardiac Rehab Center   (Netherlands)

Author keywords

Apoptosis; Lymphocyte activation; Soluble Fas; Systemic lupus erythematosus

Indexed keywords

BASILIXIMAB; CD20 ANTIGEN; CD38 ANTIGEN; FAS ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; MONOCLONAL ANTIBODY CD14; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD38; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY HLA DR; OKT 4; OKT 8; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032191331     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1998.0233     Document Type: Conference Paper

References (34)

1. + cells to support autoantibody synthesis. Arthritis Rheum. 33: 1216-1225
2. 2. Mountz J.D., Wu J., Cheng J., Zhou T. 1994. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum. 37: 1415-1420
3. 3. Nagata S., Golstein P. 1995. The Fas death factor. Science 267: 1449-1456
4. 4. Suda T., Nagata S. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179: 873-879
5. 5. Ohsako S., Hara M., Harigarai M., Fukasawa C., Kashiwazaki S. 1994. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin. Immunol. Immunopathol. 73: 109-114
6. 6. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S.-I., Sameshima M., Hase A., Seto Y., Nagata S. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243
7. 7. Zhou T., Bluethmann H., Eldridge J., Berry K., Mountz J.D. 1991. Abnormal thymocyte development and production of autoreactive T cells in TCR transgenic autoimmune mice. J. Immunol. 147: 466-474
8. 8. Sobel E.S., Cohen P.L., Eisenberg R.A. 1993. Lpr T cells are necessary for autoantibody production in lpr mice. J. Immunol. 150: 4160-4167
9. 9. Reap E.A., Sobel E.S., Cohen P.L., Eisenberg R.A. 1993. Conventional B cells, not B-1 cells are responsible for producing autoantibodies in lpr mice. J. Exp. Med. 177: 69-78
10. 10. Ravirajan C.T., Sarraf C.E., Anilkumar T.V., Golding M.C.H., Alison M.R., Isenberg D.A. 1996. An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 105: 306-312
11. 11. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A.G., Debatin K.M., Fischer A., de Villartay J.P. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349
12. 12. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middelton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946
13. 13. Mysler E., Bini P., Drappa J., Ramos P., Friedman S.M., Krammer P.H., Elkon K.B. 1994. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J. Clin. Invest. 93: 1029-1034
14. 14. Emlen W., Niebur J., Kadera R. 1994. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152: 3685-3692
15. 15. Lorenz H.M., Grunke M., Hieronymous T., Hermann M., Kuhnel A., Manger B., Kalden J.R. 1997. In vitro apoptosis from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum. 40: 306-317
16. 16. Spronk P.E., Horst G., van der Gun B.T.F., Limburg P.C., Kallenberg C.G.M. 1996. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus. Clin. Exp. Immunol. 104: 446-453
17. 17. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. 1994. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762
18. 18. Kovacs B., Szentendrei T., Bednarek J.M., Pierson M.C., Mountz J.D., Vogelsang S.A., Tsokos G.C. 1997. Persistent expression of a soluble form of Fas/APO1 in continuously activated T cells from a patient with SLE. Clin. Exp. Rheumatol. 15: 19-23
19. 19. Jodo S., Kobayashi S., Kayagaki N., Ogura N., Feng Y., Amasaki Y., Fujisaku A., Azuma M., Yagita H., Okumura K., Koike T. 1997. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin. Exp. Immunol. 107: 89-95
20. 20. Tokano Y., Miyake S., Kayagaki N., Nozawa K., Morimoto S., Azuma M., Yagita H., Takasaki Y., Okumura K., Hashimoto H. 1996. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J. Clin. Immunol. 16: 261-265
21. 21. Rose M., Latchman D.S., Isenberg D.A. 1997. Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 6: 717-722
22. 22. Knipping E., Krammer P.H., Onel K.B., Lehman T.J.A., Mysler E., Elkon K.B. 1995. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 38: 1735-1737
23. 23. Goel N., Ulrich D.T., St Clair E.W., Fleming J.A., Lynch D.H., Seldin M.F. 1995. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum. 38: 1738-1743
24. 24. Lopik Th. V., Bijl M., Smeets-Boeihe L., Hart M., Gesner T., Creasy A., Kallenberg C., Aarden L., Smeenk R. 1998. Changing soluble Fas levels in longitudinal series of plasma samples of systemic lupus erythematosus (SLE) patients. J. Rheumatol. In press
25. 25. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277
26. 26. Bombadier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 35: 630-640
27. 27. Bootsma H., Spronk P.E., Limburg P.C., Gmelig Meyling F.H.J., Kater L., Derksen R.H.W.M., Kallenberg C.G.M. 1995. Prevention of relapses of systemic lupus erythematosus (SLE) by treatment with corticosteroids based on changes of anti-dsDNA levels: a long-term controlled prospective study. Lancet 345: 1595-1599
28. 28. Feltkamp T.E.W., Kirkwood T.B.L., Maini R.N., Aarden L.A. 1988. The first international standard for antibodies to double stranded DNA. Ann. Rheum. Dis. 47: 740-746
29. 29. Miyawaki T., Uehara T., Nibu R., Tsuji T., Yachie A., Yonehara S., Taniguchi N. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149: 3753-3758
30. 30. Dhein J., Walczak H., Bäumler C., Debatin K.M., Krammer P.H. 1995. Autocrine T-cell suicide mediated by APO-1/(FAS/CD95). Nature 373: 438-441
31. 31. Kovacs B., Liossis S.N.C., Dennis G.J., Tsokos G.C. 1997. Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. J. Autoimmunity 25: 213-221
32. 32. Rubin L.A., Kurman C.C., Fritz M.E., Biddisson W.E., Boutin B., Yarchoan R., Nelson D.L. 1985. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135: 3172-3177
33. 33. Spronk P.E., ter Borg E.J., Limburg P.E., Kallenberg C.G.M. 1994. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4, and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus; a prospective study. Ann. Rheum. Dis. 53: 235-239
34. 34. Boehme M.W.J., Waldherr R., Kist A., Riedl S., Walter-Kirst R., Kempeni J., Raeth U. 1996. Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNFa therapy. Eur. J. Clin. Invest. 26: 404-410